Czech Republic-based drugmaker Zentiva and German pharmaceutical trader Phoenix joined forces this week for an inaugural annual partnership meeting in Prague to kick off a strategic partnership between the two healthcare companies in Europe.
"At Phoenix group we believe that Zentiva is an excellent fit for partnering at European level, thanks to their strong heritage, broad portfolio of generics and OTC medicines and presence in a large number of European markets," says Nemanja Jankovic, head of partnerships at Phoenix.
The first projects to commence under the strategic partnership are being rolled out in certain Central & Eastern European (CEE) markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze